- Home
- DBI vs LYEL Comparison
DBI vs LYEL Comparison
Compare DBI & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBI
- LYEL
- Stock Information
- Founded
- DBI 1991
- LYEL 2018
- Country
- DBI United States
- LYEL United States
- Employees
- DBI N/A
- LYEL N/A
- Industry
- DBI Clothing/Shoe/Accessory Stores
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- DBI Consumer Discretionary
- LYEL Health Care
- Exchange
- DBI Nasdaq
- LYEL Nasdaq
- Market Cap
- DBI 292.2M
- LYEL 263.9M
- IPO Year
- DBI 1991
- LYEL 2021
- Fundamental
- Price
- DBI $5.65
- LYEL $0.62
- Analyst Decision
- DBI Hold
- LYEL Sell
- Analyst Count
- DBI 2
- LYEL 2
- Target Price
- DBI $5.75
- LYEL $1.00
- AVG Volume (30 Days)
- DBI 2.3M
- LYEL 1.5M
- Earning Date
- DBI 12-10-2024
- LYEL 11-07-2024
- Dividend Yield
- DBI 3.57%
- LYEL N/A
- EPS Growth
- DBI N/A
- LYEL N/A
- EPS
- DBI N/A
- LYEL N/A
- Revenue
- DBI $3,050,038,000.00
- LYEL $63,000.00
- Revenue This Year
- DBI $0.78
- LYEL N/A
- Revenue Next Year
- DBI $3.19
- LYEL N/A
- P/E Ratio
- DBI N/A
- LYEL N/A
- Revenue Growth
- DBI N/A
- LYEL N/A
- 52 Week Low
- DBI $4.36
- LYEL $0.58
- 52 Week High
- DBI $11.57
- LYEL $3.26
- Technical
- Relative Strength Index (RSI)
- DBI 50.89
- LYEL 27.76
- Support Level
- DBI $5.28
- LYEL $0.58
- Resistance Level
- DBI $6.21
- LYEL $0.95
- Average True Range (ATR)
- DBI 0.51
- LYEL 0.07
- MACD
- DBI 0.02
- LYEL -0.02
- Stochastic Oscillator
- DBI 57.05
- LYEL 6.48
About DBI Designer Brands Inc.
Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in three reportable segments: the U.S. Retail segment, the Canada Retail segment, and the Brand Portfolio segment. The U.S. Retail segment operates the DSW Designer Shoe Warehouse banner through its direct-to-consumer U.S. stores and e-commerce site. The Canada Retail segment operates The Shoe Company and DSW banners through its direct-to-consumer Canada stores and e-commerce sites. The Brand Portfolio segment earns revenue from the sale of wholesale products to retailers, commissions for serving retailers as the design and buying agent for products under private labels, and the sale of branded products through its direct-to-consumer e-commerce sites.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.